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Background The use of repeated intravenous infusions of EDTA, which has become known as "chelation therapy," has been promoted for treating intermittent claudication as well as a wide range of other disorders. Multiple reports of excellent results in large numbers of patients have encouraged the use of this regimen. The lack of well-controlled studies substantiating the benefits of this treatment has limited its use mainly to private clinics. The aim of the study was to assess the benefits of chelation therapy in patients with intermittent claudication.
Methods and Results A double-blind, randomized, controlled trial included 32 patients with intermittent claudication who were randomized to a treatment group (15) and a control group (17) . Main outcome measures were subjective and measured walking distances and ankle/brachial pulse indices. Other outcome measures included lifestyle and subjective parameters of improvement, cardiac function, ECG, renal function, hematology, blood glucose, and lipid biochemistry. No clinically significant differences in main outcome measures between chelation therapy and placebo groups were detected up to 3 months after treatment. Measures of mood state, activities of daily living, and quality of life factors were not consistently affected by chelation therapy. An equal proportion (13%) of each group thought that they had received the active agent. The proportion of patients showing an improvement in walking distance was not significantly different between the chelation group (60%) and the control group (59%).
Conclusions Chelation therapy has no significant beneficial effects over placebo in patients with intermittent claudication. (Circultion. 1994; 90:1194 -1199 Key Words * atherosclerosis * peripheral vascular disease * lifestyle C helation therapy, a program of repeated intravenous administration of ethylenediaminetetraacetic acid (EDTA) together with vitamin supplementation, has been promoted as an effective treatment for a wide range of clinical conditions.1-3 In atherosclerotic and specifically peripheral vascular disease, very marked benefits have been reported.45 Despite the considerable enthusiasm of the proponents of chelation therapy, there has been a notable lack of acceptance of its use by the majority of medical practitioners for conditions other than heavy metal poisoning.67 This has lead to a long-standing debate in the medical literature, the press, and the political arena about the efficacy of, the access to, and the funding for this treatment in a number of countries.7-13 Numerous clinics dedicated to this therapy have been established, but state funding has not been forthcoming.
EDTA has many biochemical effects, including chelation of calcium and other divalent ions, free radical scavenging, inhibition of lipid peroxidation, cell membrane stabilization, and calcium channel blockade. '4-'6 These effects of EDTA have given broad scope to the possible reasons why chelation therapy should have a clinical benefit. Plausible as these hypotheses may be, they lack the supportive evidence of relevant in vivo experiments and appropriately designed clinical trials. Many claims for the efficacy of chelation therapy have been based on uncontrolled studies, although some of these have included substantial numbers of patients3 (L.T. Chappell and J.P. Stahl, unpublished data, 1993).
A small double-blind trial in 1990 reported significant success with chelation therapy in a group of patients with peripheral vascular disease.17 Subsequently, a larger multicenter study published in 1991 failed to demonstrate a benefit.18"9 Aspects of this study have been criticized by proponents of chelation therapy. 20 We now report a single-center, double-blind, randomized, controlled trial in a group of patients with intermittent claudication.
Methods
Patients who had been fully investigated for intermittent claudication were recruited from the Dunedin Hospital peripheral vascular disease clinic. Participation in the trial was offered to patients with peripheral atherosclerotic disease, which was confirmed by arteriography, for whom other invasive interventions were not indicated. Patients were required to have no other debilitating disease affecting waLking, to be greater than 45 years of age, to be nondiabetic, and to have no significant renal disease. All patients were counseled to anticipate a positive effect of chelation therapy, and they received the promotional literature usually provided by chelation therapy clinics.21 Appropriate dietary recommendations and a requirement to stop smoking were made.
The study received ethical approval, and patients were required to give written informed consent before being included. A requirement for entry into the trial was a variation of less than 20% in measured walking distance in three consecutive noninvasive vascular laboratory assessments, performed on different days. Further workup and subsequent observations included segmental pressure and pulse volume plethysmography and femoral and posterior tibial artery pulsatility indices.22 These were measured at rest and after exercise on a treadmill at 4 km/h and 10% gradient. Lowerlimb skin blood flow and transcutaneous oxygen tensions were measured.23 24 Levels of cardiac function were monitored during a modified Bruce exercise test25 in the cardiology department. Plasma lipid, lipid peroxides, and oxidized low-density lipoprotein levels were measured. 26 The effects of chelation therapy on behavior and attitudes related to lifestyle were investigated by means of previously validated, self-administered questionnaires. The following were included: the main instrument from the Life in New Zealand National Survey, which included questions on physical activity, perceived fitness, smoking, alcohol consumption, and dietary practices in the previous 4 weeks27; the 12-item form of the General Health Questionnaire, which assessed anxiety-depression in the previous 4 weeks28; and the Profile of Mood States, which measured feelings of tension, anger, depression, confusion, fatigue, and vigor in the previous 2 days. 29 In addition, several questions making use of visual analogue scales were devised to gauge patients' global feelings of well-being and the effect of poor circulation on their social and private leisure activities. All questions were assembled into one booklet and were completed twice before treatment and then once at each of the assessment stages. The patients' perception of the treatment group to which they were assigned was assessed by means of a questionnaire after the 3-month visit.
Patients were randomized in blocks of 10, and preparation of the assigned infusions was conducted independently by the hospital pharmacist. The 500-mL infusion for the active treatment group was pharmaceutically prepared and contained 3.0 g disodium EDTA, 0.76 g magnesium chloride, and 0.84 g sodium bicarbonate in normal saline. The placebo was an intravenous infusion of 500 mL normal saline. In addition, both groups received Parentrovite (thiamine hydrochloride 250 mg, riboflavine phosphate [sodium salt] 5.5 mg, pyridoxine hydrochloride 50 mg, ascorbic acid [sodium salt] 500 mg, nicotinamide 160 mg, sodium pantothenate 5 mg, glucose anhydrous 1000 mg, sodium metabisulphite 4 mg) in each infusion. The infusions were indistinguishable by container, labeling, or color. Each patient received a total of 20 infusions, each given over 3 to 3.5 hours, twice per week for 10 weeks. Daily oral supplements of vitamins as recommended by the American Academy of Medical Preventics and American Board of Chelation Therapy30 were given throughout the period of treatment. Urinalysis, standard hematology, renal function, and serum calcium, zinc, magnesium, and iron levels were measured weekly and at follow-up assessments to monitor for the possible toxic side effects of chelation therapy. 31 Patients were supervised throughout the duration of each infusion with hourly pulse and blood pressure monitoring. Patient assessments and data analyses were carried out by different staff groups who worked independently and were blind to the identity of the treatment and control groups.
The major end points for the study were: measured walking distances, defined as the total distance the patient was able to walk at 4 km/h on a treadmill at 10% gradient (1) to onset of pain and (2) before stopping because of disabling claudication; subjective walking distance, defined as the distance the patients considered they were able to walk before stopping because of claudication; and ankle/brachial indices (ABI) measured at rest and immediately after the treadmill exercise.
The sample size required for the study was calculated from an algorithm that combined retest reliability of outcome measures, type I error rate, and power to detect a minimum difference in effect size (lAmean/SD) between treatment and control groups. Retest of the first 20 patients entering the study gave reliability correlations of 0.98 and 0.96 for the outcome measures of absolute walking distance and ABI, respectively. With the usual assumptions of 80% power and type I error of 5%, these reliabilities implied that a controlled trial involving at least 30 patients would detect effect-size differences of 0.2 for walking distance and 0.3 for ABI. Such effect sizes are regarded as small on theoretical grounds. 32 They equate with differences in improvement in walking distance and ABI of approximately 10% and 5%, respectively, which are less than what is usually regarded as clinically significant and also far less than the improvements that have been claimed for chelation therapy (for walking distance, 100% to 400% in 90% of patients3'17; for ABI, up to 86% in 93% of patients4).
Assessments after entry into the trial were carried out after 10 infusions, at the completion of treatments, and at 3, 6, and 12 months after treatment. The code was broken when the required number of patients had completed the 3-month posttreatment assessment, but only after the statistical analysis had been performed. The results up to this time are presented here. The 6-and 12-month assessments are still in progress.
Data were analyzed with the Statistical Analysis System (SAS Institute). The significance of differences in effects between the chelation and control groups, and any overall changes in both groups with time, was tested with repeatedmeasures ANOVA. Walking distances were log transformed and other variables not normally distributed were rank transformed to reduce effects of heteroscedasticity and skewness on subsequent analyses. Bilateral measures of peripheral vascular disease were grouped by better and worse limbs as determined by the postexercise pulse index before infusions. Effect sizes were calculated to standardize comparison of changes in mean values of variables following treatment; magnitudes of effect size were interpreted according to the criteria of Cohen.32 Continuity-adjusted x2 tests were performed to test the significance of the difference of frequency of improvement in each group. The type I error rate for declaring statistical significance was set to 0.05.
Results
Of the 59 patients invited to enter the trial, 32 met the repeated assessment criteria for inclusion, agreed to take part, and completed treatment. Exclusions made before infusions were due to inconsistent walking distances (9), rest pain (2), cardiac disease limiting exer- cise tolerance (4), detection of impaired renal function or diabetes (4), intercurrent illness (2), and unavailability to participate in the full protocol (6) . Characteristics of the patients in the chelation and control groups are shown in Table 1 .
There was a significant improvement in the walking distances in both groups at the end of the infusion program. However, the major end points of improved absolute and subjective walking distances as well as postexercise ABI were not significantly different in the two groups at any time during treatment or follow-up ( Table 2) . Changes in skin blood flow, transcutaneous oxygen, and pulse volume recordings before and after exercise were also not significantly different between the groups immediately after treatment (Fig 1) or at the later assessment. At 3 months after treatment, resting ABI of both the better and worse legs showed some improvement in the chelation group (Table 2) . A clinically significant improvement of at least 0.1 in the resting ABI of the worse leg was observed in two patients in each group. The femoral pulsatility index (normal range, 6 to 15) in the worse leg had improved from 3.3±0.9 to 4.2±1.2 in the chelation group and decreased from 4.1±0.8 to 3.6+0.9 in the control group (P<.01). Similar trends were noted in the femoral artery of the better leg and in the posterior tibial arteries, but these did not reach statistical significance. No other parameters of peripheral vascular function differed at 3 months, and the percentage of patients that showed any increase in walking distance at this assessment was 60% and 59% for the chelation and control groups, respectively. Changes in lifestyle parameters at the end of the treatment period were not significantly different between the two groups. The measure of tension increased in the control group and decreased in the chelation group, an effect that was no longer evident at 3 months. tScores on visual analogue scale: 0 (no effect) to 10 (very severe). *Percent of maximum possible score. §Score on 5-point scale: 1 (much less) to 5 (much more). liScore on 7-point scale: 1 (very much less) to 7 (very much more). ¶Score on visual analogue scale: 0 (worst) to 10 (best).
As shown in Table 3 , at 3 months the levels of usual activity and low-intensity and mild-to-moderate exercise had all improved in the chelation group. The effect sizes for these changes were moderate (Fig 2) . Chelation therapy had no benefit at this time on assessed levels of fatigue, physical well-being, mood, general quality of life, or on the specific effect of arterial disease on quality of life, work, home management, and social or private leisure activities.
There were no significant differences between the groups in patients' knowledge of the nature of their infusions: 12.5% of both groups thought that they had received chelation therapy; 68% of the placebo group and 50% of the treatment group thought they had received the placebo; the remaining patients were unsure which treatment they had received. There were no complications or withdrawals from the study in either group up to the 3-month assessment. 
Discussion
After 10 weeks of treatment, chelation therapy provided no immediate benefit on peripheral vascular hemodynamics, functional measures of activity, lifestyle, quality of life, or perceptions of health related to peripheral vascular disease when compared with a control group. Particularly for the major end points of waLking distances and postexercise ABI, this study had the power to demonstrate whether this therapy was as effective as reported. It appears that chelation therapy does not provide that benefit for patients with peripheral vascular disease.
One of the difficulties in assessing the benefit of therapy for peripheral vascular disease is the wellrecognized improvement in walking distances achieved with conservative management. The improvement in the chelation group if viewed alone could readily, but mistakenly, have been attributed to the EDTA. This highlights the necessity of controlled studies for evaluation of therapies for intermittent claudication.
Additional benefits 3 or more months after chelation have been claimed (M.E. Godfrey, personal communication, 1992). Therefore, it was important to carry out follow-up well after treatment was completed. In this study, no more clinically significant late benefits were seen in the chelation group than were observed in the control group. Most of the peripheral hemodynamic measures remained indistinguishable, and there were no detectable benefits in quality of life or in most of the activities of daily living. At this time, the patients were also unable to distinguish the therapy that they thought they had received.
However, there was an interesting small improvement in the resting ABI and femoral artery pulsatility indices observed 3 months after chelation. Whether these are in any way related to the moderate treatment effect size noted in some levels of activity at this stage remains unclear. The reliability of outcome measurements in the study certainly had the power to detect benefits much smaller than those claimed for chelation. The significance of these positive late findings will require further study.
A relatively unique aspect of this study has been the concurrent evaluation of the patients' mood state, lifestyle, diet, and activities of daily living and their perceptions of the influence of the treatment on these factors. In view of the wide range of actions put forward by which chelation could possibly improve patient response, these assessments were considered to be particularly important. For example, changes in muscle metabolism or mood state could well modify the performance and perception of activities of daily living without direct changes in hemodynamic function. No such alternative benefits were identified. Differences in dietary food items and quantities as well as cooking habits and alcohol consumption during the study period were also excluded. The effect on lipid metabolism and cardiac function as well as follow-up after 1 year will be reported subsequently.
Whereas there is a general consensus for the protocol for the administration of chelation therapy, there is also still some minor diversity of practice. The study tested the essential component of the therapy (EDTA) in an appropriate formulation and amount and with strict blinding. The specific regimens of vitamin supplementation, dietary advice, and general support given to all the subjects should not be relevant to the comparative outcome. The previous encouraging reports of chelation therapy for the treatment of intermittent claudication have not been substantiated by this study.
